Why is BIOA down?
Down 47% in 3 months while the S&P 500 fell 2%.
- Its Nov 5 results:
−3Long-term trend
BIOA's Quality Score fell 1 point on Fri, Nov 13, to -6. Its average daily range rose to 8.0%, with a $108M loss over four quarters and no positive free cash flow.
Follow BIOA's trial news. Pro members can get an alert when BioAge Labs files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 47% in 3 months while the S&P 500 fell 2%.
−3Long-term trend
| Holding it back | 28.1% more shares than a year ago |
| Latest filing | 8-K, Nov 5 |
Mon Nov 16: UBS Global Biopharma Conference 2026Investor conference · date confirmed.
Expected to report Wed Mar 24, after the close
1 more date ahead: the conference, for Pro members.
About 13 quarters
An officer, Shane Barton, sold 62,566 shares on Jun 30, under a planned sale. 6 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
BIOA is #224 of 270 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 224 |
Expected to report Wed Mar 24, after the close (in 128 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.73 a share, from $0.56.
“The $1.8 million decrease was primarily due to a $1.7 million cumulative catch-up adjustment recorded in connection with a September 2026 amendment to the Novartis Agreement, which added $0.9 million of research funding and expanded the research activities to be performed, increasing the total estimated effort required to satisfy the performance obligation.”
BIOA's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The $11.7 million increase in research and development expenses was primarily attributable to a $13.2 million increase in direct costs related to BioAge’s BGE-102 program associated with clinical trial costs for the Company’s ongoing QUELL-CV and QUELL-DME trials and drug product manufacturing costs.”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -4.2% | -3.6% | +2.0% |
| Aug 5, 2026 | -0.7% | +2.6% | -4.5% |
| May 8, 2026 | -1.7% | +0.9% | +5.0% |
Sales grew in 2025, to $9M. It lost money in both years.
RSI 41.9, MACD above signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BIOA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
“The biotechnology and pharmaceutical industries are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property.”
BIOA scores -6 today, which Breakaway calls Poor. It is #224 of 270 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 47% in 3 months while the S&P 500 fell 2%. Cash lasts about 13 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BIOA scores -6 today, which Breakaway calls Poor (below zero). That is #224 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BIOA's -6.
Expected to report Wed Mar 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. BIOA closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.